| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | 7.86 M USD | 3.45 M USD | -552958 USD | -756716 USD | — |
| Depreciation & Amortization | 495698 USD | 525295 USD | 607138 USD | — | — |
| Stock-Based Compensation | 3.96 M USD | 20.87 M USD | — | — | — |
| Capital Expenditures | 479034 USD | 576674 USD | 291856 USD | — | — |
| Cash Flow from Investing | -478438 USD | -565034 USD | 130.58 M USD | -3.00 M USD | — |
| Cash Flow from Financing | 4.03 M USD | 2.02 M USD | -130.26 M USD | 3.00 M USD | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | — | — | 133.12 M USD | — | — |
| Free Cash Flow | 7.38 M USD | 2.87 M USD | -844814 USD | — | — |
Cure Pharmaceutical Holding Corp. is a biopharmaceutical company focused on the development and commercialization of innovative drug delivery systems. It aims to improve patient adherence and experience by providing new methods for drug delivery, such as oral thin films and transdermal systems. Cure Pharmaceutical's technologies are designed to enhance the bioavailability, efficacy, and safety of existing pharmaceutical compounds while also providing a platform for new drug formulations. This plays a vital role in several therapeutic areas, including pain management, oncology, and central nervous system disorders. By leveraging cutting-edge technology and partnerships within the pharmaceutical industry, Cure Pharmaceutical Holding Corp. contributes to the advancement of personalized and precision medicine, addressing unmet medical needs and broadening the spectrum of delivery options in healthcare markets.